The launch coincides with World Kidney Day, a global event dedicated to raising awareness about the importance of kidney health and the urgent need for improved prevention, early diagnosis, and treatment of kidney diseases.
PromarkerD is a clinically validated blood test that can predict the risk of developing chronic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. This early warning provides healthcare professionals with a critical window to intervene, enabling better patient management and reducing the risk of severe kidney complications, including kidney failure and the need for dialysis or transplant.
Back in 2021, MTPConnect’s Accelerator program, BioMedTech Horizons (BMTH), provided funding to help progress the test’s development, and we are excited to be following Proteomics journey of success.
Diabetes is the leading cause of chronic kidney disease globally, and the burden is particularly acute in Australia, where more than 1.3 million people are living with diabetes (1). According to the International Diabetes Foundation, more than one in two adults with type 2 diabetes will develop kidney disease (2), posing a significant threat to both quality of life and healthcare resources.
The launch of PromarkerD in Australia addresses this critical need by empowering doctors to identify at-risk patients early, enabling timely intervention to slow or prevent disease progression.
The commercial launch of PromarkerD into its home market is a key milestone in Proteomics International’s global commercialisation strategy. Having built a fully integrated digital solution for direct-to-consumer engagement the Company is now well-positioned to support the early detection of diabetic kidney disease for Australian patients.
PromarkerD will initially be available through referral by a healthcare professional in Western Australia and the Northern Territory, before the test is made available nationwide.
Proteomics International Managing Director Dr Richard Lipscombe said, “We are excited to officially launch PromarkerD in Australia, particularly on World Kidney Day, which underscores the importance of early diagnosis and prevention. Diabetic kidney disease is a major public health challenge, and PromarkerD offers a highly innovative, accurate, and accessible way to identify those most at risk.
“By enabling proactive management, we aim to reduce the personal and financial costs associated with this life-threatening condition,” said Dr Lipscombe.
For more information read the ASX Announcement.
1 www.aihw.gov.au/reports/diabetes/diabetes/contents/summary#prevalence
2 International Diabetes Federation 2021